Our list of all the latest Apple Watch deals for Black Friday & Cyber Monday, including savings on GPS & GPS + Cellular Apple Watch models
Here’s a round-up of all the best Apple Watch deals for Black Friday & Cyber Monday 2020, featuring discounts on the Apple Watch 6, 5, 4, 3, and SE smartwatches in 42mm, 38mm, 40mm & 44mm case sizes. Links to the top deals are listed below.
Best Apple Watch Deals:
Save $330 off on the latest Apple Watch Series 6, SE & more top models at ATT.com - click the link for the latest deals on Apple Watches including Apple Watch SE, Nike SE, Series 6 and Nike Series 6 models
Save on the latest Apple Watches at Verizon.com - check the latest deals on Series 3, 4, 5, 6 & SE Apple Watches including buy one get 50% off another
Save up to 23% on Apple Watches including the Apple Watch 6, SE, 5, 4 & 3 at Amazon - click the link for live prices on the latest Apple Watch Series 6 & SE and older series 5, 4, and 3 smartwatches
Save on Apple Watches with any iPhone purchase at Verizon.com - check the latest deals on various Apple Watch models including SE, Series 6, Series 5, Series 4 and Series 3
Save on Apple Watch Series 5 at Verizon.com - check the latest deals on Apple Watch Series 5 available in regular and Nike sport bands, and 40mm and 44mm case sizes
Save up to 23% on Apple Watch Series 5 at Amazon - click the link for live prices on Apple Watch Series 5 including deals on GPS and GPS + Cellular models
Save on Apple Watch Series 6 at Verizon.com - check the latest prices on Apple Watch Series 6 available in a wide range of case colors and materials, including gold stainless steel and red aluminum
Save $330 off on the Apple Watch Series 6 & Nike Series 6 Apple Watch at ATT.com - Black Friday deals are here! Check out deals on the latest Series 6 40mm, 44mm & Nike models
Save up to $20 on the top-rated Apple Watch Series 6 at Amazon - see the latest deals on Apple Watch Series 6 including GPS and GPS + Cellular models
Save on Apple Watch Series 3 models at Amazon - see the latest deals on Watch Series 3 available in space gray and silver aluminum in 38mm and 42mm size options
Save on Apple Watch Series 3 at Verizon.com - check the latest deals on Apple Watch Series 3 available in 42mm and 38mm case sizes
Save $330 on the Apple Watch SE & Nike SE at ATT.com - Black Friday deals are here! Check out the latest deals on the Apple Watch SE including 40mm & 44mm case sizes
Save on the Apple Watch SE at Verizon.com - click the link for live prices on Apple Watch SE space gray aluminum, silver aluminum, and gold aluminum cases and sport bands and loops
Save on Apple Watch Series 4 at Verizon.com - click the link for live prices on Apple Watch Series 4 available in 40mm and 44mm case sizes, and milanese loop and sport band options
Save up to $330 on Apple Watch Series 4 at ATT.com - check live prices on the Apple Watch Series 4 available in 44mm case size and silver aluminum color
Save up to $50 on the Apple Watch Series 6, SE & Apple Watch Nike at BHPhotoVideo.com - see the live prices on a wide range of Apple watches
Searching for more deals? Click here to see the entire range of active deals at Walmart’s Black Friday & Cyber Monday sale and click here to check out Amazon’s current Black Friday & Cyber Monday deals. Spending Lab earns commissions from purchases made using the links provided.
About Spending Lab: Spending Lab research and report on online sales events. As an Amazon Associate and affiliate Spending Lab earns from qualifying purchases.
Contact: Andy Mathews (email@example.com)
Wells Fargo & Company (NYSE: WFC) today announced the appointment of six new Corporate Risk leaders as part of its enhanced Risk model to further strengthen the independent oversight of all risk-taking activities and a more comprehensive view of risk across the company. In addition, the company announced that Mike Roemer, the current Chief Compliance Officer, has decided to leave Wells Fargo following a transition period.
"Our new model will strengthen our centralized, independent risk management program, provide greater consistency in how we manage risk across our businesses, and better position us for the future,” said Chief Risk Officer (CRO) Mandy Norton.
The model consists of five line-of-business CROs, along with other teams aligned by risk type, each reporting to Norton. The new leaders, who will all report to Norton, are:
Paula Dominick, who will join Wells Fargo as Chief Compliance Officer in October. Dominick was most recently Chief Compliance Officer of Credit Suisse USA and previously held leadership roles at Bank of America, Goldman Sachs, and Morgan Stanley. In this role, Dominick will be responsible for oversight of all regulatory compliance risks for Wells Fargo.
Brian King, who will join Wells Fargo as CRO for Consumer & Small Business Banking in October. King was most recently CRO and Head of Finance for the Consumer Business at Goldman Sachs and previously held risk leadership roles at JPMorgan Chase.
Ellen Koebler, who will join Wells Fargo as CRO for Commercial Banking in September. Koebler was previously Deputy CRO at Truist, CRO for SunTrust Banks, and held leadership roles at E*Trade, JPMorgan Chase, First Union, and Shell Oil & Shell Chemical Companies.
Prasanna Someshwar, who will join Wells Fargo as CRO for Wealth & Investment Management in October. Someshwar previously held various risk leadership roles at JPMorgan Chase, including CRO and Chief Credit Officer for Wealth Management/Private Bank.
Jeff Colson, who has been named CRO for Finance, joining the risk team in September following a transition period from his current role. Colson was most recently Head of Capital Management at Wells Fargo, and his successor will be named shortly. Colson joined Wells Fargo in 2015, and he previously held executive financial and risk management positions at Bank of America.
Patrick Dillon, who has been named Enterprise Testing & Validation leader, effective immediately. Dillon joined Wells Fargo’s risk organization in 2018 and was previously in compliance leadership roles at PNC Financial Services and Bank of America Merchant Services. In this role, Dillon will lead the team responsible for the development and design of methodologies and standards for review activities across the company and provide strategic leadership of significant enterprise-wide testing programs.
The new CROs will each provide independent, holistic risk leadership and oversight for their respective business lines and functional areas, creating streamlined interaction with independent risk management and a comprehensive view of risks across each of the businesses. The CROs will work in strong partnership with leaders who will continue to oversee market, credit, operational, compliance, strategic, and model risk holistically across the entire company.
"These new leaders bring impressive experience, diverse insights, and strong leadership skills to their roles,” said Norton. "They will each play an important part on the risk leadership team under our newly enhanced organizational structure as we strengthen our independent risk management function and better position how we manage risk for the future.”
The new leaders were named following the May 2020 announcement of the enhanced Corporate Risk model, which noted that Kevin Reen would join Wells Fargo as CRO of Consumer Lending and that Bill Juliano would join Wells Fargo as chief operational risk officer. A search for the new CRO for Corporate & Investment Banking remains underway.
About Wells Fargo
Wells Fargo & Company (NYSE: WFC) is a diversified, community-based financial services company with $1.97 trillion in assets. Wells Fargo’s vision is to satisfy our customers’ financial needs and help them succeed financially. Founded in 1852 and headquartered in San Francisco, Wells Fargo provides banking, investment and mortgage products and services, as well as consumer and commercial finance, through 7,300 locations, more than 13,000 ATMs, the internet (wellsfargo.com) and mobile banking, and has offices in 31 countries and territories to support customers who conduct business in the global economy. With approximately 266,000 team members, Wells Fargo serves one in three households in the United States. Wells Fargo & Company was ranked No. 30 on Fortune’s 2020 rankings of America’s largest corporations. News, insights and perspectives from Wells Fargo are also available at Wells Fargo Stories.
Additional information may be found at www.wellsfargo.com | Twitter: @WellsFargo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005834/en/
Quidel Corporation (NASDAQ: QDEL) ("Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont, and found no testing site- or product-related issues with the Sofia® 2 instrument or the Sofia® SARS Antigen FIA.
Quidel received a complaint in Vermont regarding false positive discrepant results among patients who were subsequently tested and found negative by PCR testing. Taking every complaint submission seriously, Quidel promptly entered the complaint into its Quality Management System and worked with the testing site to identify a potential root cause.
Quidel examined the complaint thoroughly, including an inspection of the testing site, analysis of the site’s data, and a review of approximately 110,000 data points generated at 526 sites in 33 other states currently using Quidel’s product. The investigation found that there were no issues with either the testing facility or with the quality of the Sofia products used. The results of the investigation determined that no further actions were necessary, and results were provided to the Vermont Department of Health, the Centers for Disease Control and Prevention, and the U.S. Food and Drug Administration.
"Quidel takes every complaint seriously and endeavors to identify the root cause of any complaint received,” said Douglas Bryant, president and CEO of Quidel Corporation. "We conducted a very thorough investigation for this unique complaint in Vermont and believe that it was highly likely that our Sofia® results were true positives and that the subsequent PCR method used to re-test was at risk of providing inaccurate results.”
Quidel currently sells the Sofia® SARS Antigen FIA in the United States under Emergency Use Authorization (EUA) by the FDA.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, COVID-19, influenza, respiratory syncytial virus, Strep A, lyme, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's Triage® system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio and to explore exciting employment opportunities, visit quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation: the impact of the novel virus (COVID-19) global pandemic; an inability to agree on a definitive agreement or meet key deliverables and milestones under the NIH’s RADx-ATP contract; adverse changes in competitive conditions, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, lower than anticipated market penetration of our products, our reliance on sales of our influenza and other respiratory or novel virus diagnostic tests, fluctuations in our operating results resulting from the timing of the onset, length and severity of cold and flu seasons, seasonality, government and media attention focused on influenza and other respiratory or novel viruses and the related potential impact on humans from such viruses, the quantity of our product in our distributors’ inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development, acquisition and protection of proprietary technology rights; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our exposure to claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us, including the ongoing litigation between us and Beckman Coulter, Inc.; intellectual property risks, including but not limited to, infringement litigation; our need for additional funds to finance our capital or operating needs; the financial soundness of our customers and suppliers; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; failures or delays in receipt of new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the "FDA”) or other regulatory authorities or loss of any previously received regulatory approvals or clearances or other adverse actions by regulatory authorities; changes in government policies; costs of and adverse operational impact from failure to comply with government regulations in addition to FDA regulations; compliance with government regulations relating to the handling, storage and disposal of hazardous substances; third-party reimbursement policies and potential cost constraints; our failure to comply with laws and regulations relating to billing and payment for healthcare services; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance; costs and disruptions from failures in our information technology and storage systems; our exposure to data corruption, cyber-based attacks, security breaches and privacy violations; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, compliance with legal requirements, tariffs, exposure to currency exchange fluctuations and foreign currency exchange risk, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, social, political and economic instability, increased financial accounting and reporting burdens and complexities, taxes, and diversion of lower priced international products into U.S. markets; changes in tax rates and exposure to additional tax liabilities or assessments; risks relating to our acquisition and integration of the Triage MeterPro Cardiovascular and toxicology business and B-type Naturietic Peptide assay business (the "Triage and BNP Businesses”); that we may have to write off goodwill relating to our acquisitions; our ability to manage our growth strategy and identify and integrate acquired companies or technologies and our ability to obtain financing; the level of our indebtedness and deferred payment obligations; our ability to generate sufficient cash to meet our debt service and deferred and contingent payment obligations; that our Revolving Credit Facility is secured by substantially all of our assets; the agreements for our indebtedness place operating and financial restrictions on us and our ability to operate our business; that an event of default could trigger acceleration of our outstanding indebtedness; that we may incur additional indebtedness; increases in interest rate relating to our variable rate debt; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and the indenture governing our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; our intention of not paying dividends; and our ability to identify and successfully acquire and integrate potential acquisition targets. Forward-looking statements typically are identified by the use of terms such as "may,” "will,” "should,” "might,” "expect,” "anticipate,” "estimate,” "plan,” "intend,” "goal,” "project,” "strategy,” "future,” and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the "SEC”) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005721/en/